[±Ù°Å±â¹Ý ÀÓ»óÁú¹® ´äº¯]
°£¼¼Æ÷¾ÏÁ¾(Locally advanced hepatocellular carcinoma) ȯÀÚ¿¡°Ô °£µ¿¸ÆÁÖÀÔ µ¿½Ã Ç×¾ÏÈÇйæ»ç¼±¿ä¹ýÀÌ »ýÁ¸À²¿¡ ¹ÌÄ¡´Â ÀÓ»óÈ¿°ú
(Clinical Benefit of Hepatic Arterial Infusion Concurrent Chemoradiotherapy in Locally Advanced Hepatocellular Carcinoma)
ÀÓ»óÁú¹®
|
±¹¼ÒÀûÀ¸·Î ÁøÇàµÈ °£¼¼Æ÷¾ÏÁ¾(Locally advanced hepatocellular carcinoma, LAHCC) ȯÀÚ¿¡°Ô °£µ¿¸Æ ÁÖÀÔ µ¿½Ã Ç×¾ÏÈÇйæ»ç¼±¿ä¹ý(Hepatic Arterial Infusion Concurrent Chemoradiotherapy, CCRT) Ä¡·á°¡ »ýÁ¸À²(Overall survival, OS)À» ³ôÀ̴µ¥ È¿°úÀûÀԴϱî?
|
±Ù°Å±â¹Ý ´äº¯
|
±¹¼ÒÀûÀ¸·Î ÁøÇàµÈ °£¾ÏȯÀÚ Áß CCRTÄ¡·á¸¦ Àû¿ëÇÑ ±×·ìÀº ±×·¸Áö ¾ÊÀº ±×·ìº¸´Ù »ýÁ¸À²ÀÌ ÀǹÌÀÖ°Ô Çâ»óµÇ¾úÀ½À» ³ªÅ¸³»¾ú½À´Ï´Ù.
|
¼ÁöÁ¤º¸
|
Clinical Benefit of Hepatic Arterial Infusion Concurrent Chemoradiotherapy in Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. DOI: https://doi.org/10.4143/crt.2014.276
|
¿¬±¸¸ñÀû
|
LAHCC ȯÀÚ¿¡°Ô CCRT Ä¡·á°¡ OS¿¡ ¹ÌÄ¡´Â È¿°ú
|
¿¬±¸¼³°è
|
A Cohort Study: A Propensity Score Matching Analysis (1992³â~2008³â)
|
¿¬±¸´ë»ó
|
LAHCC ȯÀÚ 857¸í
|
½ÃÇ豺 ÁßÀç
|
¾Ï¼¾ÅÍ(the Yonsei Cancer Center, YCC)ÀÚ·á: 1992³âºÎÅÍ 2008³â LAHCC 106¸í
|
´ëÁ¶±º ÁßÀç
|
KLCSG ±¹°¡¾ÏÀÚ·á HCC cohort: 2003³âºÎÅÍ 2005³â LAHCC 751¸í
|
Æò°¡ÁöÇ¥
|
»ýÁ¸À²(Overall survival rates between the two groups)
|
ÁÖ¿ä°á°ú
|
5³â µ¿¾ÈÀÇ ÄÚȣƮ ÀÚ·á¿Í µÎ°³ÀÇ µ¥ÀÌÅͺ£À̽º ÀÚ·á(Yonsei Cancer Center, YCC and Korean Liver Cancer Study Group, KLCSG)¸¦ ¹ÙÅÁÀ¸·Î ºÐ¼®ÇÑ °á°ú, ±¹¼ÒÀûÀ¸·Î ÁøÇàµÈ °£¾ÏȯÀÚ Áß CCRTÄ¡·á¸¦ Àû¿ëÇÑ ±×·ìÀº ±×·¸Áö ¾ÊÀº ±×·ìº¸´Ù »ýÁ¸À²ÀÌ ÀǹÌÀÖ°Ô Çâ»óµÇ¾úÀ½À» ³ªÅ¸³»¾ú½À´Ï´Ù(median OS, 11.4 months; 5-year OS, 10.4%) had significantly better OS than the non-CCRT group (median OS, 6.6 months; 5-year OS, 8.5%; p=0.02).
|
±Ù°Å¼öÁØ
|
Moderate
|
ÀÛ¼ºÀÚ
|
ÀÇ°úÇבּ¸Á¤º¸¼¾ÅÍ(MedRIC)
Copyright © 2015. Medical Research Information Center (MedRIC) Editors
|